Compare Diageo plc (DEO) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Diageo plc vs TransMedics Group Inc — how do they compare? Diageo plc trades at $93.47 (market cap $53.05B), while TransMedics Group Inc trades at $87.57 (market cap $3.10B). The key difference: Diageo plc is far larger — about 17.1× TransMedics Group Inc's market cap, and Diageo plc pays a 3.5% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals.
| DEO | TMDX | |
|---|---|---|
Market Cap | $53.05B | $3.10B |
Sector | Technology | Technology |
52-Week High | $115.33 | $150.42 |
52-Week Low | $72.47 | $61.99 |
Enterprise Value | $72.54B | $3.49B |
Dividend Yield | 3.5% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Diageo (DEO) trades at $93.61, down 3.6% over 24 hours, with a bullish technical signal from moving averages but overbought RSI readings. The company reported mixed FY2026 results with a 2% organic sales decline but 2% operating profit growth, supported by cost savings. A new $1 billion savings plan and focus on spirits and Guinness aim to drive a turnaround, with cash flow from operations strong at $4.4 billion in 2026.
The outlook is cautiously optimistic, with analyst consensus leaning buy (49%) amid execution of the cost-cutting strategy. Risks include North America weakness and competitive pressures, but valuation metrics like P/E of 30.5 reflect growth expectations. The stock offers potential for recovery if management delivers on efficiency gains and market share stabilization.
TransMedics Group (TMDX) trades at $86.43, down 2.24% amid recent earnings misses but maintains strong analyst support with a $99.57 consensus target. The stock shows bullish technical signals with support at $84-87, though RSI levels suggest overbought conditions. Fundamentally, the company demonstrates robust profitability with 58.69% gross margins and 22.69% net income margins, despite recent quarterly earnings falling short of expectations.
Investment outlook remains positive given strong institutional backing and growth potential in organ transplant technology, though risks include ongoing fiduciary investigations and margin pressure from increased operating costs. The stock offers 15% upside to consensus targets but requires monitoring of Q3 earnings performance and legal developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Diageo plc
Diageo is a global leader in beverage alcohol with an outstanding collection of brands including Johnnie Walker, Smirnoff, and Guinness. It operates a vast portfolio of spirits and beers across more than 180 countries.
Read more on DEO →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
